Clinical Trials Logo

Congenital Hyperinsulinism clinical trials

View clinical trials related to Congenital Hyperinsulinism.

Filter by:

NCT ID: NCT01070758 Completed - Clinical trials for Congenital Hyperinsulinism

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Start date: February 2010
Phase: Phase 4
Study type: Interventional

The purpose of our study is to evaluate the efficacy and safety of Lanreotide Autogel in children with congenital hyperinsulinism already treated with Octreotide by pump. Congenital hyperinsulinism is a genetic disorder characterized by inappropriate insulin secretion resulting in persistent hypoglycemia (low blood sugars. Patients exposed to recurrent hypoglycemic episodes are at increased risk of developmental disorders, so identification and prompt management of patients are essential. Many patients are treated with the somatostatin analog Octreotide which is administered by continuous infusion using a pump (we use an insulin pump). This treatment may pose a huge burden and be stressful for patients and families as it demands intensive daily care. In an effort to simplify the daily care of our patients and improve their quality of life we will study the efficacy and safety of Lanreotide Autogel - a long-acting somatostatin analog that can be administered by injection once a month

NCT ID: NCT00987168 Completed - Clinical trials for Congenital Hyperinsulinism

Sandostatine® LP and Hyperinsulinism

Start date: May 2009
Phase: Phase 2
Study type: Interventional

To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.

NCT ID: NCT00897676 Completed - Clinical trials for Congenital Hyperinsulinism

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism. Funding Source - FDA Office of Orphan Products Development (OODP).

NCT ID: NCT00674440 Completed - Hyperinsulinism Clinical Trials

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Start date: December 2004
Phase: Phase 2
Study type: Interventional

Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.

NCT ID: NCT00571324 Completed - Clinical trials for Congenital Hyperinsulinism

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Start date: August 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.